Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Beleave Inc    BE   CA0775611084

Delayed Quote. Delayed  - 04/21 10:04:59 pm
2.39 CAD   -1.65%
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Beleave Inc.: No Material Change

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2017 | 08:11pm CEST

Beleave Inc. (CNSX: BE) at the request of the Investment Industry Regulatory Organization of Canada wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

Consistent with the Company’s press release dated September 26, 2016, the Company continues work with Health Canada towards the scheduling of a pre-licensing inspection of its proposed facility.

About Beleave Inc.

Beleave, Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ ACMPR“). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“ FAM“) has applied for a license to cultivate and sell medical marihuana pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and has been issued an affirmation letter from Health Canada prior to a request for a pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.

Forward-Looking Statements

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the ACMPR licensing process and meeting the requirements of the ACMPR. No assurances are given as to the anticipated timing of delivering the confirmations to Health Canada described in this press release nor the anticipated timing of any pre-licensing inspection. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Connect with Beleave Inc. (CNSX:BE) to receive an Investor Presentation.

The post Beleave Inc.: No Material Change appeared first on Investing News Network.

© 2017 Investing News Network. All Rights Reserved., source Investing News Network

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BELEAVE INC
03/06 BELEAVE : and Ryerson University Continue Research and Development of Industrial..
02/17 BELEAVE INC. : No Material Change
02/08 BELEAVE : and Ryerson University Collaborator Begin Patent Work by Expanding on ..
More news
Sector news : Bio Therapeutic Drugs
04/22DJNovartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ( CAD)
Sales 2017 -
EBIT 2017 -2,90 M
Net income 2017 -2,90 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 0
Capi. / Sales 2018 -
Capitalization -
More Financials
Chart BELEAVE INC
Duration : Period :
Beleave Inc Technical Analysis Chart | BE | CA0775611084 | 4-Traders
Full-screen chart
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 1,80  
Spread / Average Target
Consensus details
EPS Revisions
More Estimates Revisions
Sector and Competitors
1st jan.Capitalization (M$)
BELEAVE INC70.71%0
AMGEN, INC.9.71%118 044
CELGENE CORPORATION5.62%95 114
GILEAD SCIENCES, INC.-7.93%86 186
REGENERON PHARMACEUTIC..0.83%39 263
ACTELION LTD26.98%30 294
More Results